Compare Immunovant Inc. Common Stock (IMVT) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Intuit Inc. — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Intuit Inc. trades at $303.94 (market cap $79.43B). The key difference: Intuit Inc. is far larger — about 12× Immunovant Inc. Common Stock's market cap, and Intuit Inc. pays a 1.86% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Intuit Inc. for 66 Days on average.
| IMVT | INTU | |
|---|---|---|
Market Cap | $6.62B | $79.43B |
Volume | 1,131,364 | 3,518,398 |
Sector | Health | Technology |
52-Week High | $44.96 | $683.39 |
52-Week Low | $17.03 | $255.07 |
Typical Hold Time | 0 Days | 66 Days |
Enterprise Value | $5.72B | $80.65B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Intuit (INTU) trades at $303.88, up 4.85% today, with strong fundamental performance including 21.3% net income margin and consistent earnings beats. The stock shows bullish technical momentum with resistance at $308 and support at $293. Recent financials reveal robust revenue growth from $18.8B in 2025 to projected $21.4B in 2026, though legal challenges from class action lawsuits present near-term headwinds.
Outlook remains positive with analyst consensus target of $379.68 (25% upside), driven by AI integration and QuickBooks monetization. Key risks include litigation overhang and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, supporting long-term growth trajectory despite technical overbought signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
